Thirty years of the human immunodeficiency virus epidemic and beyond

Abstract

Expanded preventative and therapeutic efforts will be critical to maintaining the momentum in the fight against human immunodeficiency virus (HIV), concludes Fariba Younai of the University of California at Los Angeles, USA. Younai has reviewed the scientific and medical advances that help HIV patients in controlling their disease, as well as assist patients and health-care workers in containing the spread of this virus. She noted that existing treatments control but do not eliminate infection. Younai also listed causes for concern, including high disease burdens and mortality rates in the developing world. She explored the value of preventative strategies, such as drug prophylaxis to prevent HIV transmission by pregnant mothers to their children, and male circumcision. She also examined experimental efforts to eradicate latent viral reservoirs that might eventually give rise to AIDS.

Keywords

human immunodeficiency virus / treatment / prevention / global impact / antiretrovirals / epidemiology

References

[1] Centers for Disease Control Kaposi’s sarcoma Pneumocystis pneumonia among homosexual men—New York City and California. Morbid Mortal Wkly Rep, 1981, 30(25): 305-308.

[2] Vieira J, Frank F, Spira TJ. Acquired immunodeficiency in Haitians: opportunistic infections in previously healthy Haitian immigrants. N Engl J Med, 1983, 308(3): 125-129.

[3] Centers for Disease Control Pneumocystis carinii pneumonia among persons with hemophilia A. Morbid Mortal Wkly Rep, 1982, 31(27): 365-367.

[4] Centers for Disease Control Update on acquired immune deficiency syndrome (AIDS) among patients with hemophilia A. Morbid Mortal Wkly Rep, 1982, 31(48): 644-646.

[5] Centers for Disease Control Update on acquired immune deficiency syndrome (AIDS) among patients with hemophilia A. Morbid Mortal Wkly Rep, 1982, 31(48): 652.

[6] Centers for Disease Control Possible transfusion-associated acquired immune deficiency syndrome (AIDS)—California. Morbid Mortal Wkly Rep, 1982, 31(48): 652-654.

[7] Centers for Disease Control Update on acquired immune deficiency syndrome (AIDS)—United States. Morbid Mortal Wkly Rep, 1982, 31(37): 507-508.

[8] Centers for Disease Control Immunodeficiency among female sexual partners of males with acquired immune deficiency syndrome (AIDS)—New York. Morbid Mortal Wkly Rep, 1983, 31(52): 697-698.

[9] Harris C, Small CB, Klein RS. Immunodeficiency in female sexual partners of men with the acquired immunodeficiency syndrome. N Engl J Med, 1983, 308(20): 1181-1184.

[10] Barri-Sinoussi F, Chermann JC, Rey F. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 1983, 220(4599): 868-871.

[11] Popovic M, Sarngadharan MG, Read E. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science, 1984, 224(4648): 497-500.

[12] Coffin J, Haase A, Levy JA. Human immunodeficiency viruses. Science, 1986, 232(4751): 697.

[13] Barre-Sinoussi F, Mathur-Wagh U, Rey F. Isolation of lymphadenopathy-associated virus (LAV) and detection of LAV antibodies from US patients with AIDS. J Am Med Assoc, 1985, 253(12): 1737-1739.

[14] Clavel F, Guétard D, Brun-Vézinet F. Isolation of a new human retrovirus from West African patients with AIDS. Science, 1986, 233(4761): 343-346.

[15] Keele BF, van Heuverswyn F, Li Y. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science, 2006, 313(5786): 523-526.

[16] Plantier JC, Leoz M, Dickerson JE. A new human immunodeficiency virus derived from gorillas. Nat Med, 2009, 15(8): 871-872.

[17] Santiago ML, Range F, Keele BF. Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Taï Forest, Côte d’Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2. J Virol, 2005, 79(19): 12515-12527.

[18] Piot P. Ingredients fro a perfect storm. Science, 2011, 23(334): 1642.

[19] Pépin J. The expansion of HIV-1 in colonial Leopoldville, 1950s: driven by STDs or STD control. Sex Transm Infect, 2012, 88(4): 307-312.

[20] UNAIDS. World AIDS day report 2011. Geneva: UNAIDS. Available at http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdf (accessed 5 December 2012).

[21] UNAIDS. AIDS epidemic update. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2009. UNAIDS/09.36E/JC1700E, November 2009. Geneva: UNAIDS. Available at http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf (accessed 5 December 2012).

[22] Gonda MA. Molecular genetics and structure of the human immunodeficiency virus. Electron Microsc Tech, 1988, 8(1): 17-40.

[23] Montagnier L. Lymphadenopathy-associated virus: from molecular biology to pathogenicity. Ann Intern Med, 1985, 103(5): 689-693.

[24] Gelderblom HR, Hausmann EH, Ozel M. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology, 1987, 156(1): 171-176.

[25] Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev, 1993, 57(1): 183-289.

[26] Maddon P, Dalgleish A, McDougal JS. The T4 gene encodes the AIDS receptor and is expressed in the immune system and the brain. Cell, 1986, 47(3): 333-348.

[27] Gao G, Wieczorek L, Peachman KK. Designing a soluble near full-length HIV-1 GP41 trimer. J Biol Chem, 2012, 288(1): 234-246.

[28] Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol, 1999, 17: 657-700.

[29] Sattentau QJ, Moore JP. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med, 1991, 174(2): 407-415.

[30] Berkowitz RD, Alexander S, Bare C. CCR5- and CXCR4-utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo. J Virol, 1998, 72(12): 10108-10117.

[31] Alkhatib G, Combadiere C, Broder CC. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science, 1996, 272(5270): 1955-1958.

[32] Hwang S, Boyle T, Lyerly H. Identification of the V3 loop as the primary determinant of cell tropism in HIV-1. Science, 1991, 253(5015): 71-74.

[33] Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fuseons, antigens, and immunogens. Science, 1998, 280(5371): 1884-1888.

[34] Hunt PW, Brenchley J, Sinclair E. Relationship between T cell activation and CD4⁺ T cell count in HIV seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis, 2008, 197(1): 126-133.

[35] Choudhary SK, Vrisekoop N, Jansen CA. Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol, 2007, 81(16): 8838-8842.

[36] Quillent C, Oberlin E, Braun J. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet, 1998, 351(9095): 14-18.

[37] Schliekelman P, Garner C, Slatkin M. Natural selection and resistance to HIV. Nature, 2001, 411(6837): 545-546.

[38] Faure E, Royer-Carenzi M. Is the European spatial distribution of the HIV-1-resistant CCR5-Delta32 allele formed by a breakdown of the pathocenosis due to the historical Roman expansion. Infect Genet Evol, 2008, 8(6): 864-874.

[39] Thèze J, Chakrabarti LA, Vingert B. HIV controllers: a multifactorial phenotype of spontaneous viral suppression. Clin Immunol, 2011, 141(1): 15-30.

[40] International HIV Controllers Study Pereyra F, Jia X, McLaren PJ. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science, 2010, 330(6010): 1551-1557.

[41] Zhang H, Yang B, Pomerantz RJ. The cytidine deaminase induces hypermutation in newly synthesized HIV-1 RNA. Nature, 2003, 424(6944): 94-98.

[42] Jin X, Wu H, Smith H. APOBEC3G levels predict rates of progression to AIDS. Retrovirology, 2007, 4: 20-27.

[43] Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature, 2008, 451(7177): 425-530.

[44] Schrofelbauer B, Yu Q, Zeitlin SG. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol, 2005, 79(17): 10978-10987.

[45] US Food and Drug Administration. Antiretroviral drugs used in the treatment of HIV infection. Silver Spring: US FDA. Available at http://www.fda.gov/ForConsumers/byAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm118915.htm (accessed 5 December 2012).

[46] Hammer SM, Saag MS, Schechter M. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA, 2006, 296(7): 827-843.

[47] AIDS Info. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville: AIDS Info. Available at http://aidsinfo.nih.gov/guidelines (accessed 12 July 2012).

[48] Hosseinipour MC, van Oosterhout JJ, Weigel R. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS, 2009, 23(9): 1127-1134.

[49] Laspia MF, Rice AP, Mathews MB. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell, 1989, 59(2): 283-292.

[50] Huigen MC, Kamp W, Nottet HS. Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection. Eur J Clin Invest, 2004, 34(1): 57-66.

[51] Fiorentino DF, Zlotnik A, Vieira P. IL-10 acts on the antigen-processing cell to inhibit cytokine production by Th1 cells. Immunology, 1991, 146(10): 3444-3451.

[52] Alfano M, Poli G. The cytokine network in HIV infection. Curr Mol Med, 2002, 2(8): 677-689.

[53] Division of Global HIV/AIDS, Center for Global Health Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. MMWR Recomm Rep, 2012, 61(RR-5): 1-40.

[54] Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem, 2000, 275(27): 20251-20254.

[55] Dubé MP, Parker RA, Mulligan K. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS, 2005, 19(16): 1807-1818.

[56] Grunfeld C, Rimland D, Gibert CL. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immun Def Syndr, 2007, 46(3): 283-290.

[57] Lohse N, Hansen AB, Pedersen G. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med, 2007, 146(2): 87-95.

[58] Lundgren JD, Battegay M, Behrens G. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med, 2008, 9(2): 72-81.

[59] Grinspoon SK, Grunfeld C, Kotler DP. State of the science conference. Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS; executive summary. Circulation, 2008, 118(6): 198-210.

[60] Ghani KR, Oliver RT, Chinegwundoh F. Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study. BJU Int, 2008, 101(12): 1519-1523.

[61] Walker UA, Tyndall A, Daikeler T. Rheumatic conditions in human immunodeficiency virus infection. Rheumatology, 2008, 47(7): 952-959.

[62] Powles T, Robinson D, Stebbing J. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol, 2009, 27(6): 884-890.

[63] DAD Study Group Friis-Møller N, Reiss P. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med, 2007, 356(17): 1723-1735.

[64] Hammer SM, Eron JJ Jr, Reiss P. Antiretroviral treatment of adult HIV infection, 2008 recommendations of the international AIDS Society-USA panel. JAMA, 2008, 300(5): 555-570.

[65] French MA, Lenzo N, John M. Immune restoration disease after the treatment of immunodeficient HIV infected patients with highly active antiretroviral therapy. HIV Med, 2000, 1(2): 107-115.

[66] Ratnam I, Chiu C, Kandala NB. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis, 2006, 42(3): 418-427.

[67] Lipman M, Breen R. Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis, 2006, 19(1): 20-25.

[68] Leidner RS, Aboulafia DM. Recrudescent Kaposi’s sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS, 2005, 19(10): 635-644.

[69] Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. Washington: Office of National AIDS Policy, 2010. Available at http://www.whitehouse.gov/administration/eop/onap/nhas (accessed 5 December 2012).

[70] Mazzeo CI, Flanagan EH, Bobrow EA. How the global call for elimination of pediatric HIV can support HIV-positive women to achieve their pregnancy intentions. Reprod Health Matters, 2012, 20(39 Suppl): 90-102.

[71] World Health Organization. New guidance on prevention of mother-to-child transmission of HIV and infant feeding in the context of HIV, 2010. Geneva: World Health Organization. Available at http://www.who.int/hiv/pub/mtct/PMTCTfactsheet/en/index.html (accessed 12 December 2012).

[72] UNAIDS. Countdown to zero: global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. Geneva: UNAIDS, 2011. Available at http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20110609_JC2137_Global-Plan-Elimination-HIV-Children_en.pdf (accessed 10 December 2012).

[73] Branson BM, Handsfield HH, Lampe MA. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. Morbid Mortal Wkly Rep, 2006, 55(RR-14): 1-17.

[74] Cohen MS, Chen YQ, McCauley M. Prevention of HIV-1infection with early antiretroviral therapy. N Engl J Med, 2011, 365(6): 493-505.

[75] Government of Kenya. Kenya AIDS Indicator Survey 2007. Nairobi: Government of Kenya, 2009, Available at http://nascop.or.ke/library/3d/Official_KAIS_Report_20091.pdf (accessed 17 December 2012).

[76] Centers for Disease Control and Prevention. Diagnoses of HIV infection and AIDS in the United States and Dependent Areas, 2010. HIV Surveillance Report, Volume 22. Atlanta: CDC. Available at http://www.cdc.gov/hiv/surveillance/resources/reports/2010report/index.htm (accessed 5 December 2012).

[77] CDC Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. Morbid Mortal Wkly Rep, 2005, 54(RR-02): 1-20.

[78] CDC Interim guidance: preexposure prophylaxis for prevention of HIV infection in men who have sex with men and women. Morbid Mortal Wkly Rep, 2011, 60(3): 65-68.

[79] CDC Interim Guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. Morbid Mortal Wkly Rep, 2012, 61(31): 586-589.

[80] Botswana Harvard AIDS Institute. Botswana Harvard AIDS Institute Partnership: Mochudi Prevention Project. Gaborone: Botswana Harvard AIDS Institute, 2011. Available at http://www.hsph.harvard.edu/bhp/research/hiv_prevention/mochudi_prevention.html (accessed 3 July 2012).

[81] AIDS HIV Prevention Trial Network. HTPN 071, population effects of antiretroviral therapy to reduce HIV transmission (PopART): a cluster randomized trial of the impact of a combination prevention package on population-level HIV incidence in Zambia and South Africa. Available at http://www.hptn.org/research_studies/hptn071.asp (accessed 3 July 2013).

[82] Walensky RP . Combination HIV prevention: the value and interpretation of mathematical models. Curr HIV/AIDS Rep 2013; [Epub ahead of print].

[83] Hütter G, Nowak D, Mossner M. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med, 2009, 360(7): 692-698.

[84] Chung J, Rossi JJ, Jung U. Current progress and challenges in HIV gene therapy. Future Virol, 2011, 6(11): 1319-1328.

[85] Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet, 2011, 12(5): 329-340.

[86] Caseiro MM, Nelson M, Diaz RS. Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials. J Infect, 2012, 65(4): 326-335.

[87] Klibanov OM, Williams SH, Iler CA. Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection. Curr Opin Investig Drugs, 2010, 11(8): 940-950.

[88] Monogram Biosciences. Trofile ^TM – Monogram’s co-receptor tropism assay. San Francisco: Monogram Biosciences. Available at http://www.monogrambio.com/414.aspx. (accessed 21 December 2012).

[89] Boesecke C, Pett SL. Clinical studies with chemokine receptor-5 (CCR5)-inhibitors. Curr Opin HIV AIDS, 2012, 7(5): 456-462.

[90] Schanzer J, Jekle A, Nezu J. Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother, 2011, 55(5): 2369-2378.

[91] Zhang MY, Yuan T, Li J. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. PLoS ONE, 2012, 7(9): e44241.

[92] Pace CS, Fordyce MW, Franco D. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr, 2012, 62(1): 1-9.

[93] Monajemi M, Woodworth CF, Benkaroun J. Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment. Retrovirology, 2012, 9: 35.

[94] Ali A, Wang J, Nathans RS. Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication. Chem Med Chem, 2012, 7(7): 1217-1229.

[95] Shankar EM, Velu V, Vignesh R. Recent advances targeting innate immunity-mediated therapies against HIV-1 infection. Microbiol Immunol, 2012, 56(8): 497-505.

[96] Ellegård R, Shankar EM, Larsson M. Targeting HIV-1 innate immune responses therapeutically. Curr Opin HIV AIDS, 2011, 6(5): 435-443.

[97] Shi J, Zhou J, Shah VB. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol, 2011, 85(1): 542-549.

[98] Hu G, Li X, Zhang X. Discovery of inhibitors to block interactions of HIV-1 integrase with human LEDGF/p75 via structure-based virtual screening and bioassays. J Med Chem, 2012, 55(22): 10108-10117.

[99] Palmer S, Josefsson L, Coffin JM. HIV reservoirs and the possibility of a cure for HIV infection. J Intern Med, 2011, 270(6): 550-560.

[100] Joos B, Fischer M, Kuster H. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A, 2008, 105(43): 16725-16730.

[101] Dhamija N, Rawat P, Mitra D. Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication. Subcell Biochem, 2013, 61: 479-505.

[102] Llibre JM, Buzón MJ, Massanella M. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther, 2012, 17(2): 355-364.

[103] Gutiérrez C, Díaz L, Vallejo A. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS ONE, 2011, 6(12): e27864.

[104] Brenchley JM, Price DA, Schacker TW. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med, 2006, 12(12): 1365-1371.

[105] Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol, 2008, 214(2): 231-241.

[106] Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. Br Med J, 2009, 338: a3172.

[107] Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe?. Nat Immunol, 2006, 7(3): 235-239.

[108] Kvale D, Ormaasen V, Kran AB. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. AIDS, 2006, 20(6): 813-820.

[109] Ganesan A, Crum-Cianflone N, Higgins J. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis, 2011, 203(6): 756-764.

[110] Dan H, Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature, 2008, 455(7213): 613-619.

[111] Mascola JR, Snyder SW, Weislow OS. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis, 1996, 173(2): 340-348.

[112] Moore JP, Cao Y, Qing L. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol, 1995, 69(1): 101-109.

[113] Priddy FH, Brown D, Kublin J. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis, 2008, 46(11): 1769-1781.

[114] The rgp120 HIV Vaccine Study Group Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis, 2005, 191(5): 654-665.

[115] Fauci AS . The release of new data from the HVTN 502 (STEP) HIV vaccine study. NIH News 2007. Available at http://www3.niaid.nih.gov/about/directors/news/step11707.htm (accessed 17 December 2012).

[116] Li Y, Migueles SA, Welcher B. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med, 2007, 13(9): 1032-1034.

[117] van Gils MJ, Sander RW. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virol, 2013, 435(1): 46-56.